How people with psoriatic arthritis respond to one biologic treatment after another
Follows adults with psoriatic arthritis starting biologic treatments, including how well each one works.
Plain-language title generated from the registry record
Registry title: A Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis
Key facts
- Where
- Bath, United KingdomSee the site
Where in United Kingdom
- Royal United Hospitals Bath NHS Foundation TrustBath, United KingdomNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Royal United Hospitals Bath NHS Foundation Trust
- Trial code
- NCT07417995
- Record updated
- 13 May 2026
- Original description
The goal of this observational study is to evaluate how well advanced therapies work in adults with psoriatic arthritis (PsA) who are starting a biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) as part of routine care.Read full original descriptionShow less
STRIDE-PsA: A Study of Treatment Response and Immunogenicity in Sequential Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drug (b/tsDMARD) Exposure in Psoriatic Arthritis
The goal of this observational study is to evaluate how well advanced therapies work in adults with psoriatic arthritis (PsA) who are starting a biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) as part of routine care.
The main questions are:
* Do treatment responses differ according to the number of previous advanced therapies? * Can anti-drug antibodies (ADAs) or blood drug levels help predict treatment effectiveness?
Researchers will compare participants receiving earlier-line versus later-line advanced therapies to assess differences in treatment response and antibody development.
Participants will allow collection of routine clinical assessment data, complete questionnaires on symptoms and quality of life, and provide blood samples before treatment and at 12 weeks.
Inclusion: Age ≥18 years; Clinical diagnosis of PsA meeting CASPAR criteria; Starting a new b/tsDMARD, irrespective of line of therapy.
Exclusion: Switching b/tsDMARD therapy for psoriasis or spondyloarthritis alone, without active psoriatic arthritis; Previous treatment with the same b/tsDMARD being started at baseline; Inability or unwillingness to provide informed consent.